Clinical implications of the trial outcomes for weight management Across the STEP trials, onceweekly subcutaneous semaglutide 2.4 mg demonstrated mean weight loss of 14.9%17.4% at 68 weeks in participants without diabetes with the mean baseline weight of 100107 kg, 38 , 40 , 41 , 43 offering the potential for clinically relevant improvement for individuals with obesityrelated diseases
Additionally, seek guidance if you develop symptoms of thyroid nodules (neck lump, difficulty swallowing, persistent hoarseness), or gallbladder problems (persistent right upper quadrant pain, fever, jaundice)
The medication does not have to be forever: some patients use it as a bridge while they build new habits, others stay on longer with regular medical review
It is strongly recommended that you consult with a healthcare provider before starting Ozempic, particularly if you have pre-existing conditions or are taking other medications
Our guide on when to resume semaglutide after surgery covers pre-surgical holding periods and post-operative restart protocols